A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-1)

Trial Profile

A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-1)

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Proof of concept
  • Acronyms EASE-1
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 15 Sep 2017 Outcomes of a population PK-PD model using data from this trial designed to quantify the effect of the empagliflozin on renal glucose reabsorption in patients with type 1 diabetes and to compare results with analysis in patients with type 2 diabetes, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top